EGFR and incontinentia pigmenti: Gemma et al. reported the results of real-world data about osimertinib for EGFR T790M-positive NSCLC and revealed IP history or coexistence as factors that are potentially associated with the onset of drug-induced pneumonitis during the treatment (adjusted OR: 3.51; 95% CI: 2.10–5.87) [39].